The pharmacokinetics of pergolide in Parkinson's disease

被引:20
|
作者
Blin, O [1 ]
机构
[1] CHU Timone, CPCET, CNRS, FRE 2109,Inst Physiol & Clin Neurosci, F-13385 Marseille 5, France
关键词
dopamine agonist; pergolide; pharmacokinetics; Parkinson's disease;
D O I
10.1097/00019052-200312001-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Three decades of research have led to a fuller understanding of the pharmacokinetics of pergolide. Pergolide is rapidly absorbed following oral dosing, reaching peak plasma concentrations within 2-3 h. It is about 90% protein bound yet has negligible drug interactions. Pergolide undergoes extensive first-pass metabolism and is completely eliminated within 4-5 days. The metabolism/elimination profile varies between patients but is consistent within the individual, highlighting the importance of careful titration to an effective dose. Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia.
引用
收藏
页码:S9 / S12
页数:4
相关论文
共 50 条
  • [1] Pergolide pharmacokinetics in patients with Parkinson's disease
    Thalamas, C
    Rascol, O
    Blin, O
    Kulisevsky, J
    Rajman, I
    Brefel-Courbon, C
    [J]. MOVEMENT DISORDERS, 2002, 17 : S47 - S47
  • [2] Pergolide pharmacokinetics in patients with Parkinson's disease (PD)
    Thalamas, C.
    Rajman, I.
    Bareille, M. P.
    Mackie, A.
    Soubrouillard, C.
    Kulisevsky, J.
    Descombes, S.
    Brefel-Courbon, C.
    Fabre, N.
    Barbanoj, M. J.
    Blin, O.
    Rascol, O.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 115 - 115
  • [3] High dosage of pergolide in Parkinson's disease
    Kizilay, F
    Ozkaynak, S
    [J]. MOVEMENT DISORDERS, 2004, 19 : S274 - S274
  • [4] Pergolide monotherapy titration in Parkinson's disease
    Nausieda, P
    Stern, M
    Hubble, J
    Silver, D
    Wess, M
    Watts, R
    [J]. MOVEMENT DISORDERS, 2002, 17 : S87 - S87
  • [5] Pergolide mesylate in Parkinson's disease treatment
    Pezzoli, G
    Canesi, M
    Pesenti, A
    Mariani, CB
    [J]. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 203 - 212
  • [6] PERGOLIDE IN PARKINSON DISEASE
    LIEBERMAN, AN
    GOLDSTEIN, M
    GOPINATHAN, G
    NEOPHYTIDES, A
    LEIBOWITZ, M
    WALKER, R
    HIESIGER, E
    [J]. NEUROLOGY, 1982, 32 (04) : A182 - A182
  • [7] Pergolide: a useful agonist for the treatment of Parkinson's disease
    Bonnet, AM
    Houeto, JL
    [J]. REVUE NEUROLOGIQUE, 2002, 158 (6-7) : 744 - 745
  • [8] Pergolide -: Multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease
    Thalamas, C
    Rajman, I
    Kulisevsky, J
    Lledó, A
    Mackie, AE
    Blin, O
    Gillespie, TA
    Seger, M
    Rascol, O
    [J]. CLINICAL NEUROPHARMACOLOGY, 2005, 28 (03) : 120 - 125
  • [9] Pergolide-induced lung disease in patients with Parkinson's disease
    Kastelik, JA
    Aziz, I
    Greenstone, MA
    Thompson, R
    Morice, AH
    [J]. RESPIRATORY MEDICINE, 2002, 96 (07) : 548 - 550
  • [10] Vaivular heart disease in pergolide-treated Parkinson's disease
    Scozzafava, J
    Takahashi, J
    Johnston, W
    Puttagunta, L
    Martin, WW
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2006, 33 (01) : 111 - 113